Megan Sniecinski - Praxis Precision Chief Officer
| PRAX Stock | USD 79.45 0.21 0.26% |
Executive
Megan Sniecinski is Chief Officer of Praxis Precision Medicines
| Age | 42 |
| Address | 99 High Street, Boston, MA, United States, 02110 |
| Phone | 617 300 8460 |
| Web | https://praxismedicines.com |
Praxis Precision Management Efficiency
The company has return on total asset (ROA) of (0.392) % which means that it has lost $0.392 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6434) %, meaning that it created substantial loss on money invested by shareholders. Praxis Precision's management efficiency ratios could be used to measure how well Praxis Precision manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -1.47 in 2024. Return On Capital Employed is likely to drop to -1.84 in 2024. At this time, Praxis Precision's Total Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 108.3 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 3 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Jeffrey Fellows | Mineralys Therapeutics, Common | N/A | |
| Dr Esq | Enliven Therapeutics | 47 | |
| Jaya Goyal | PepGen | 56 | |
| Lucia Celona | Dyne Therapeutics | 58 | |
| Renate Gloggner | Molecular Partners AG | 54 | |
| Afsaneh Mohebbi | PepGen | N/A | |
| MD MBA | Eliem Therapeutics | 50 | |
| Gayathri Diwakar | Crinetics Pharmaceuticals | N/A | |
| Anne DVM | Molecular Partners AG | N/A | |
| John JD | Edgewise Therapeutics | 60 | |
| Nishi MD | Eliem Therapeutics | N/A | |
| Danielle Bradbury | Mineralys Therapeutics, Common | N/A | |
| Dana MD | Crinetics Pharmaceuticals | 68 | |
| Michelle MD | PepGen | 48 | |
| Amy Reilly | Dyne Therapeutics | 50 | |
| Daniel George | Anebulo Pharmaceuticals | 54 | |
| Emily Pimblett | Eliem Therapeutics | 40 | |
| Jennifer Huber | AN2 Therapeutics | N/A | |
| Joshua JD | AN2 Therapeutics | 46 | |
| Marc Wilson | Crinetics Pharmaceuticals | 45 | |
| Shamim MS | Stoke Therapeutics | 64 | |
Management Performance
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.39 |
Praxis Precision Med Leadership Team
Elected by the shareholders, the Praxis Precision's board of directors comprises two types of representatives: Praxis Precision inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Praxis. The board's role is to monitor Praxis Precision's management team and ensure that shareholders' interests are well served. Praxis Precision's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Praxis Precision's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dr B, CoFounder Officer | ||
| Timothy Kelly, CFO Treasurer | ||
| Nicole Sweeny, Chief Officer | ||
| Kelly McCue, Chief Officer | ||
| Alyssa Wyant, Chief Officer | ||
| Megan Sniecinski, Chief Officer | ||
| Lauren Mastrocola, VP Officer | ||
| Brian Spar, Chief Staff | ||
| Alex JD, General Secretary | ||
| Marcio MBA, CEO President | ||
| Karl Hansen, Chief Officer | ||
| Alex Kane, VP Communications |
Praxis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Praxis Precision a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.64 | ||||
| Return On Asset | -0.39 | ||||
| Operating Margin | (188.20) % | ||||
| Current Valuation | 1.13 B | ||||
| Shares Outstanding | 18.64 M | ||||
| Shares Owned By Insiders | 0.24 % | ||||
| Shares Owned By Institutions | 99.76 % | ||||
| Number Of Shares Shorted | 1.72 M | ||||
| Price To Book | 3.88 X | ||||
| Price To Sales | 925.04 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Praxis Stock Analysis
When running Praxis Precision's price analysis, check to measure Praxis Precision's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Praxis Precision is operating at the current time. Most of Praxis Precision's value examination focuses on studying past and present price action to predict the probability of Praxis Precision's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Praxis Precision's price. Additionally, you may evaluate how the addition of Praxis Precision to your portfolios can decrease your overall portfolio volatility.